William M. Garrett

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Martin Grießhammer et al. · New England Journal of Medicine · 2015 · 851 citations

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed

Herbert I. Hurwitz, Nikhil Uppal, Stephanie A. Wagner et al. · Journal of Clinical Oncology · 2015 · 279 citations · Full text

Durable Responses with the JAK1/ JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU)

Srđan Verstovšek, Francesco Passamonti, Alessandro Rambaldi et al. · Blood · 2010 · 61 citations

A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC).

Herbert I. Hurwitz, Nikhil Uppal, Stephanie A. Wagner et al. · Journal of Clinical Oncology · 2014 · 51 citations

Immunology, Pharmacotherapy, Metastatic Pancreatic Cancer +18

A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.

Srđan Verstovšek, Francesco Passamonti, Alessandro Rambaldi et al. · Blood · 2009 · 48 citations